Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Antibe Therapeutics Inc. (T:ATE)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for ATE within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Apr 19, 2024 08:00 ET
Antibe Provides Update on CCAA Proceedings
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay of proceedings (“Stay”) under the Companies’ Creditors Arrangement Act (the “CCAA”) at a hearing before the Ontario Superior Court of Justice (Commercial List) (the “Court”) on April 18, 2024.
Read full article
Apr 16, 2024 17:00 ET
Antibe Announces TSX Delisting Review
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Toronto Stock Exchange (“TSX”) is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company’s financial condition as a criterion for delisting applicable to the Company.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
--
--
--
Price to Sales - TTM
--
--
--
Price to Book - most recent quarter
--
--
--
Price to Cash Flow per share - TTM
--
--
--
Price to Free Cash Flow per share - TTM
--
--
--
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
May 15, 202400
Apr 30, 202400
Apr 15, 202400
See Short Report

Business Summary

Sector:  N/A Industry:  N/A

See business summary

 

Twitter

Search (past week) for $ATE.CA

  • No tweets found